Kineta Announces KVA12123 Monotherapy Safety And Biomarker Data From Its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Kineta has announced safety and biomarker data from its ongoing Phase 1/2 VISTA-101 clinical trial for KVA12123 monotherapy. The trial has cleared the first three monotherapy cohorts with no dose limiting toxicity and no consistent pattern of adverse events at any dose level. The clinical trial is advancing to higher monotherapy dose levels and in combination with Pembrolizumab. Initial monotherapy clinical efficacy data is anticipated in Q4 2023.
October 03, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta's ongoing Phase 1/2 VISTA-101 clinical trial for KVA12123 monotherapy has shown promising safety and biomarker data. This could potentially boost investor confidence in the company.
The positive safety and biomarker data from Kineta's ongoing Phase 1/2 VISTA-101 clinical trial for KVA12123 monotherapy indicates that the trial is progressing well. This could potentially boost investor confidence in the company, leading to a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100